Background: Treatment aimed at eradicating Helicobacter pylori infection results in lymphoma remission in most localized gastric mucosa-associated lymphoid tissue (MALT) lymphomas. The aim of this survey is to investigate the long-term effect of this therapeutic approach in a large series of patients.
Primary gastric non-Hodgkin's lymphomas represent 5% of all gastric malignancies. The most common histological subtypes are diffuse large B-cell lymphoma (DLBCL) and marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma [1] . In recent series, the latter type comprises up to more than half of cases [2, 3] .
MALT lymphoma was first described in 1983 by Isaacson and Wright [4] , who recognized a striking histological similarity between cases of immunoproliferative small intestinal disease and gastric low-grade lymphoma. In the following decade, the demonstration that Helicobacter pylori infection is a risk factor for gastric MALT lymphoma and the finding that eradication of these bacteria can result in histological lymphoma regression in most patients made this tumor a popular model of antigendriven lymphomagenesis [5] [6] [7] . The association of H. pylori with gastric MALT lymphoma led to the hypothesis that the microorganism provides an antigenic stimulus that sustains the growth of the lymphoma in the stomach, and today it is generally accepted that administration of antibiotics to eradicate H. pylori should be the sole initial treatment of gastric MALT lymphoma that is confined to the gastric wall [8] [9] [10] . In retrospective series, the patient survival following 'antiHelicobacter' therapy appeared not to be inferior when compared with local (surgery, radiation therapy) and systemic treatments (chemotherapy) [11, 12] .
More than a decade after the first employment of a combination of antibiotics and proton pump inhibitors as first-line therapy for gastric MALT lymphoma, it is nowadays possible to investigate the long-term effect of this therapeutic approach. Here, we report the clinical, endoscopic and histological characteristics and treatment outcome of front-line anti-Helicobacter therapy in 105 gastric MALT lymphoma patients after a median follow-up of 6.3 years.
patients and methods

patient selection
From July 1990 to November 2006, 156 patients with localized (i.e. disease confined to the stomach with or without involvement of the paragastric lymph nodes and with no distant lymph node involvement) marginal zone B-cell lymphoma of the MALT type of the stomach were referred to our institutions. Only the subset of 105 patients who received exclusively antiHelicobacter eradication therapy as first-line therapy was eligible for this retrospective study. This series comprises every new case of localized gastric MALT lymphoma referred to our institutions in the study period and treated with an initial anti-Helicobacter therapy, including some of the patients who have been treated in early studies of antibiotics as first-line therapy for gastric MALT lymphoma, whose initial results were reported previously [11, 13] .
staging procedures
All the patients had stage I (i.e. stomach only) or II 1 (i.e. paragastric lymph nodes involvement) according to the modified Blackledge system that is presently known as the Lugano staging system [14] using clinical examination, endoscopy, chest X-ray or computed tomography (CT) scan, abdominal ultrasound and CT scan and bone marrow biopsy. Endoscopic ultrasound was not available during most of the study period, and no patient had positron emission tomography evaluation at diagnosis. Routine laboratory tests were also carried out, including determination of lactate dehydrogenase (LDH) and b2-microglobulin in most patients. Performance status (PS) was evaluated according to Eastern Cooperative Oncology Group (ECOG) scale.
anti-Helicobacter treatment
All patients received as first-line therapy a combination of antibiotics (amoxicillin and claritromicin in 36%, metronidazole and claritromicin in 24%, amoxicillin and metronidazole in 15% and others in 16%) and proton pump inhibitors (mostly omeprazole, less commonly pantoprazole or lansoprazole). A second-line antibiotic treatment was given for patients who failed to eradicate the microorganism. Patients who did not respond to antibiotics were referred to other treatments in accordance with the local guidelines.
histological assessment
Diagnosis of lymphoma was on the basis of morphological and immunophenotypic analysis of the paraffin-embedded section according to the criteria described by Isaacson et al. [15] and subsequently included in the Revised European-American Lymphoma/World Health Organization classification. No routine molecular biology studies were carried out. The endoscopic biopsies comprised in most cases six to eight samples from every visible lesion and separate random biopsies from macroscopically normal mucosa. Helicobacter pylori detection was on the basis of histology and/or histochemistry in 85 patients. Serum antibody titer and/or breath test was used to confirm H. pylori negativity in 14 cases. No data on H. pylori at diagnosis were available for six patients.
Lymphoma remission (either complete or partial) was investigated by regular endoscopic examinations including multiple biopsies, carried out at 6-month intervals. Histological responses were graded using the Wotherspoon histological score considering scores 0-2 a complete lymphoma regression (CR), score 3 a partial remission (PR) and scores [4] [5] no response (no change) [16] . A histopathology panel composed by expert pathologists from each institution (CC, EP and LM) was established to allow a consistent and uniform application of the diagnostic criteria in all the studied cases.
statistical analysis
Statistical analysis was conducted using the STATA 5.0 software package (Computing Resource Centre, Santa Monica, CA). Overall survival (OS) was calculated according to the revised criteria for malignant lymphoma from time of diagnosis to time of death from any cause or last follow-up [17] . Follow-up was calculated as the median time to censoring using a reverse Kaplan-Meier analysis [18] . Survival probabilities were calculated using the life table method and survival curves were estimated by the method of Kaplan-Meier with upper and lower confidence bands calculated using Greenwood's approximation; differences between curves were analyzed using the log-rank test [19] . The Cox proportional hazards model was used for multivariate analysis and estimation of relative risk and its confidence interval (CI). Binomial exact 95% CIs were calculated for incidence percentages. 20-94 years) . In all patients, diagnosis was on the basis of endoscopic biopsy. One hundred patients (95%) had stage I and five (5%) stage II 1 disease (enlarged perigastric lymph nodes). PS was normal in the majority of patients (ECOG PS 0 in 89%). Serum LDH and b2-microglobulin, determined in most patients, were usually within normal limits. All patients presented with gastrointestinal symptoms (mainly abdominal pain/dyspepsia) but no B symptoms were observed (only one patient presented with weight loss due to the reduction of appetite likely associated with the gastric localization of the lymphoma). Lymphoma was most often localized in the antrum (29%) and was multifocal in 22% (Table 2 ). In two patients who had a previous partial gastrectomy because of peptic ulcer, the lymphoma arose in the gastric stump. The endoscopic pattern was most frequently consistent with erosive gastritis (55%) and ulcers (29%). Helicobacter pylori was histologically detected at lymphoma diagnosis in 85 of 99 assessable patients (86%); in six cases, this information was not available ( Table 2) .
Sixteen of 93 assessable patients (17%) had a history of systemic chronic inflammatory disease with immunity or autoimmunity disorders before the diagnosis of gastric MALT lymphoma: six had thyroiditis, three rheumatoid arthritis, one fibromyalgia, one celiac disease, one sclerodermy, one temporal arteritis, one psoriasis, one sarcoidosis and one Raynaud's syndrome.
One or more additional tumors were observed in 21 patients (22%) for a total of 26 tumors (13 diagnosed before and 13 after the gastric MALT lymphoma). Twenty-three were solid tumors (seven basal cell and one squamous cell cutaneous carcinomas, three breast, three prostate, three endometrium, one bladder, one nonsmall-cell lung cancer, one renal, one rectal, one melanoma and one gastric) and three hematological neoplasms (one Hodgkin's lymphoma, one mantle cell lymphoma and one follicular lymphoma). In addition, we also observed one case of severe gastric dysplasia and one case of monoclonal gammopathy IgG/k, both diagnosed after the MALT lymphoma. The median age for the subset of patients with additional cancers was 69 years. This high incidence of additional tumors in this population (without clear evidence of increased risk for gastric adenocarcinoma) was already known [20] . The reasons for this finding remain uncertain, but the elderly age may play a role.
treatment outcome
All patients received anti-Helicobacter treatment as the sole front-line therapy. Helicobacter pylori was eradicated in all positive patients (85 of 85) but in 19 of them a second-line antibiotic therapy was required. Symptoms disappeared or markedly diminished in almost all patients; only one complained about protracted dyspepsia after first-line therapy. The endoscopic features improved in 90% of cases.
lymphoma response to antibiotic treatment
Histological regression of the gastric lymphoma was achieved in 78 of 102 assessable patients (76%, 95% CI: 67% to 84%) with histological complete remission (CR) in 66 (Wotherspoon score 0-2) and partial remission (PR) in 12 patients (score 3).
The median time to CR was 15.5 months and its 25th and 75th percentiles were 5 and 32 months, respectively. The observed lymphoma remission rates were significantly different according to the different initial anatomical localization in the stomach (Table 3) .
For the 92 patients in whom the information on the initial lymphoma localization is available (the cases arisen in the gastric stump were also excluded from this analysis), a CR was attained in 39% of the cases with multifocal presentation (95% CI: 20% to 61%) in comparison with 63% (95% CI: 47% to 78%) for the presentation in the proximal stomach (fundus or body) and 82% (95% CI: 63% to 94%) for those in the distal organ (antrum) (P = 0.007). However, this difference seems mainly due to the lower remission rate for the cases with the disease presenting in the body, being the CR rates for fundus, body and antrum 82%, 42% and 82%, respectively.
The median follow-up time of the 78 patients who attained a lymphoma regression after antibiotics was 6.8 years; for 74 of them the results of follow-up endoscopies were available. The histological remission (Wotherspoon score 0-2) was consistently confirmed at follow-up endoscopies in 33 of these CI: 23% to 46%) had histological score fluctuations from 0 to 4, sometimes with transient histological relapses followed by spontaneous histological remissions. Sixteen patients relapsed (22%, 95% CI: 13% to 33%): 13 had a local low-grade relapse (Wotherspoon score 5), two (13% of relapses, 95% CI: 2% to 38%) had a local relapse with histological transformation to a high-grade lymphoma and one patient only had a distant relapse with axilla lymph nodes involvement. Among the 25 patients who presented an histological score fluctuation (Wotherspoon score 0-4) after initial remission, there were two patients with H. pylori reinfection, in whom Wotherspoon scores improved again after re-eradication of the microorganism with antibiotics, and one patient who developed severe gastric dysplasia. This latter was referred to partial gastrectomy. Further oncological treatments were not necessary for this group of patients as they remained asymptomatic and did not present macroscopic evidence of local or distant relapse (stable endoscopic features and absence of distant sites of disease).
outcome of patients not responding to antibiotics
In 24 patients, the histological examination of follow-up gastric biopsies always showed persistent residual lymphoma lesions (Wotherspoon score 4-5). No cases of histological transformation were observed in this group of patients. In two cases, a later H. pylori reinfection occurred and second-line antibiotics eradicated again the infection albeit with no effect on their lymphoma.
Only four of 24 patients presented a 'clinical progression' (distant and/or macroscopic): one in the gastric wall, two in regional lymph nodes and one in the bone marrow (the latter had stage II 1 disease at diagnosis). They were all referred to other treatments (Table 4) .
The other 20 cases had improved endoscopic features and symptoms relief but persistent residual lymphoma at histological examination; of them half had further therapy (Table 4 ) and half were followed on a 'watchful waiting' policy. In the latter group, one had a partial gastrectomy after the finding of in situ gastric carcinoma in one of the control biopsies.
The outcome and median follow-up according to the response to antibiotic treatment of 102 assessable patients are summarized in the flowchart in Figure 1 .
lymphoma treatments after antibiotic failure
Among the 16 relapsing patients who had a prior response to antibiotics, six of the 13 patients with histological MALT lymphoma relapse were given other treatments, five patients received chlorambucil and all achieved a CR and an additional one, after the diagnosis of follicular lymphoma (as second tumor), received anthracycline-based chemotherapy plus rituximab (R-CHOP), which resulted in a complete remission of both the gastric MALT lymphoma and the nongastric follicular lymphoma. Seven patients had transient lymphoma relapses on endoscopic repeat biopsies followed by a spontaneous remission without any further treatments. All of them are being managed with a watchful waiting policy, in one of them the relapse was accompanied by a gastric H. pylori reinfection and a second remission was obtained following eradication of the microorganism with a second-line antiHelicobacter regimen.
One of the patients with histological transformation had only palliative care (due to elderly age and comorbidities) and died of rapid progression. The other one had CHOP in another institution and we do not have further information on the outcome.
The patient with a distant relapse achieved a complete remission after single-agent chemotherapy with chlorambucil.
As above 14 of the 24 patients who never responded to H. pylori eradication had further treatment. In 10 of them, Table 4 .
Helicobacter pylori-negative and stage II 1 patients In 14 patients, H. pylori was not detected on gastric biopsy at diagnosis but, according to local policies, they were anyway given an initial antibiotic treatment. Five of them (33%, 95% CI: 12% to 62%) achieved an initial complete lymphoma regression after antibiotics, but three of five presented a local relapse and were referred to other treatments while two patients presented an histological score fluctuation (0-4) on follow-up endoscopies. Three of the five patients with stage II 1 disease presented an endoscopic improvement after antibiotics and in two of them a size reduction of perigastric lymph nodes was also observed but no complete response was documented and all five stage II 1 patients were referred to other treatments for persistence of macroscopic disease.
OS and prognostic factors
During the study time, 12 deaths were recorded, 10 in the group of 102 patients assessable for the response. The median age at death was 83.5 years (range 78-96 years). There was no significant difference in the frequency of deaths between responders (8 of 78) and nonresponders (2 of 24). Seven patients died in complete remission.
One patient died of disseminated DLBCL (transformation from MALT lymphoma could no be excluded). Five patients died of cardiovascular reasons and the others for causes reported as not related with the MALT lymphoma. At a median follow-up of 6.3 years for the entire group, the median OS was not reached. The OS rate was 92% (95% CI: 84% to 96%) at 5 years and 83% (95% CI: 70% to 91%) at 10 years after diagnosis (Figure 2 ). Univariate analysis of the clinicopathological features at presentation demonstrated a statistically significant association with a shorter OS for a previous hepatitis C virus infection (P = 0.0038), an ECOG PS >0 (P = 0.0043) and an age >60 years at presentation (P = 0.0006). At multivariate analysis, only age retained statistical significance.
discussion
Several epidemiological as well as biologic, clinicopathological and molecular studies have shown a pathogenetic role of H. pylori infection in MALT lymphomas of the gastrointestinal tract and it was repeatedly confirmed that remission of the lymphoma could be obtained in the majority of patients treated with anti-Helicobacter therapy [9, 10] , with high probabilities of long-term disease control [21, 22] . Therefore, H. pylori eradication with antibiotics is nowadays the widely accepted initial standard treatment of stage I gastric lymphoma of MALT type [8] [9] [10] . Patients with a negative H. pylori status and those with persisting gastric lymphoma infiltrates following effective anti-Helicobacter treatment are usually referred for oncological Table 4 for type of treatment and outcome; #best supportive care.
original article Annals of Oncology treatments (irradiation, surgery, chemotherapy, immunotherapy or a combination of these) [23] .
A number of molecular follow-up studies showed that postantibiotic histological and endoscopic remission does not necessarily mean a cure; we and others described a frequent long-term persistence of monoclonal B cell after histological regression of the lymphoma [24] [25] [26] but the clinical relevance of the detection of monoclonality remains unclear and in our institutions molecular studies are not part of the routine follow-up procedures. Therefore, the present report is focused on the endoscopic and histological follow-up of patients with localized (stage I-II 1 ) gastric marginal zone lymphoma after eradication of H. pylori infection.
It is worthwhile noting that the interpretation of residual lymphoid infiltrate in posttreatment gastric biopsies can be difficult and the wide range of the reported remission rates is mainly due to the lack of uniform reproducible criteria in the literature for the definition of histological remission [1] . The Wotherspoon score [16] is very useful to express the degree of confidence in the MALT lymphoma diagnosis on small gastric biopsies; however, it is sometimes difficult to apply in the evaluation of the response to therapy and other criteria have been proposed with the aim of providing clinically relevant information to the clinician [27, 28] . Nevertheless, there are no comparative studies convincingly proving the superiority of other systems in the evaluation of gastric MALT lymphoma course. In this study, we used the Wotherspoon score to define the histological responses since it was used in several previously published studies from ours and other groups [11, 13, 24, 29, 30] and has remained the standard at our institutions during most of the time span of the present study.
After antibiotics, histological remissions were observed in 76% of gastric MALT lymphomas and were associated with improvement or complete regression of endoscopic abnormalities and with resolution of symptoms. In accordance with previous reports, the length of the time necessary to obtain a remission varied from 1 month to >1 year [11] and the patients with lymph node involvement have a reduced chance of responding to antibiotics [31, 32] . Anti-Helicobacter treatment in our series was less successful in patients with multifocal disease, and in those with lymphoma presenting in the gastric body, this finding is partially in keeping with a recent study from Korea, which reported tumors in the distal stomach to be associated with more favorable response [33] .
We observed endoscopic improvement together with resolution of initial symptoms in most of the patients who did not attain a histological lymphoma remission. A watch and wait policy was adopted for many patients who did not respond immediately to antibiotics and this may explain the high number of late (more than a year after initial treatment) complete histological responses observed. It seems appropriate to distinguish the clinical (endoscopic improvement and symptoms relief) from the histological remission of lymphoma (in this study on the basis of Wotherspoon score). Our findings indicate that it is reasonable to attend at least 1 year before starting another treatment in patients who achieve a clinical (endoscopic) remission together with eradication of H. pylori albeit having persistent (residual) lymphoma at the histological level.
Approximately 40% of patients who achieved a histological remission maintained the remission during the follow-up and >30% presented a histological score fluctuation (Wotherspoon score 0-4). These patients were followed with a watch and wait policy (regular clinical and endoscopic evaluations every 6-12 months) and remained long term free of 'macroscopic' disease (i.e. had stable endoscopic features and absence of distant sites of relapse). This is supporting the hypothesis that antibiotic therapy results in a 'suppression' of the lymphoma growth and although lymphoma might be transiently found on follow-up gastric biopsies, it usually remains confined into the stomach and has no tendency to macroscopic progression. Indeed, as observed by Isaacson et al. [34] , during the follow-up of the first series of six gastric lymphoma patients treated with antibiotics, 'transient relapses are possible but tend to be self-limited especially in the absence of H. pylori reinfection'.
The clinical significance of the persistence of minimal histological residual disease is still controversial. In a small series of patients reported by Fischbach et al. [35] , a persistence of the neoplastic clone did not result in a progression of the disease after a median follow-up of 3 years. In our study, after a follow-up of >6 years, further treatments were not necessary for those patients who presented a histological score fluctuation and they were safely followed with a watch and wait policy. A major limitation of the Wotherspoon score is the lack of distinction between persistent lymphoma and the conditions defined as 'histological residual disease' according to Wundisch et al. [22] or 'responding residual disease' according to CopieBergman et al. [28] . It is plausible if not likely that many cases with Wotherspoon scores 3-4 would be described as minimal histological residuals using these criteria [22, 28] . These patients should be carefully followed with regular endoscopic evaluations [8, 10] . 
Annals of Oncology original article
Although there are not definitive therapeutic guidelines for patients who do not present an H. pylori infection at diagnosis and in general H. pylori-negative gastric MALT lymphomas do not regress after eradication therapy [31, 32] , there are some reports of lymphoma remissions also in these cases, following eradication therapy [36] . In our study, five of 14 H. pylorinegative patients achieved an initial remission after antibiotics although it was followed by relapse in three of them. We indicate that an initial attempt with antibiotics might be considered also for H. pylori-negative patients, before taking into account more aggressive approaches. Patients who failed to respond to antibiotics and patients who presented a lymphoma relapse were treated with different modalities (chemotherapy, immunotherapy and radiotherapy) in accordance with current local guidelines and it is not possible to establish which was the best therapeutic approach. In other studies, radiation therapy gave excellent results [37, 38] on localized disease and it is generally accepted as a treatment of choice for patients not responding to antibiotics [8, 10] . Rituximab seems also very active and could represent a valid alternative for the treatment of antibiotic-refractory patients [39, 40] .
In conclusion, H. pylori eradication as single therapy results in excellent long-term disease control in early-stage gastric MALT lymphoma. The observation time of this study (median follow-up time of 6.3 years) is one of the longest ever reported and gives us the possibility to evaluate the long-term effects of this therapeutic approach. Our study confirms the indolent course of gastric marginal zone B-cell lymphoma with a very low rate of distant relapses and histological transformation. Helicobacter pylori eradication therapy resulted in resolution of symptoms and improvement or resolution of endoscopic abnormalities in most of the patients treated. A long-term disease control was achieved independently of the lymphoma pathological remission status and we believe that a watch and wait policy is safe in patients with local histological residual MALT lymphoma but no endoscopic evidence of gross disease following H. pylori eradication. Our findings are therefore in keeping with a recent report of the European Gastro-Intestinal Lymphoma Study (EGILS) group [41] . They showed, in an international series of 108 stage I patients, that on the basis of a median follow-up of 4 years, most patients (94%) with minimal histological residuals of MALT lymphoma had a favorable outcome without oncological therapy. Both our findings and the EGILS results appear to indicate that a watchful waiting policy with regular endoscopic follow-up is safe in this situation and may become the standard approach. Regular endoscopic evaluation with histological examination of serial biopsies represents the most important follow-up procedure for these patients. 
